ENDRA LIFE SCIENCES INC. (NDRA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.95M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 1.27M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -6.65M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.95M | (m) | $1.27M | $-6.65M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $2.10M | (m) | $820.81K | $-6.47M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $1.85M | (m) | $329.41K | $-5.76M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $1.98M | (m) | $421.21K | $-8.44M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $2.34M | (m) | $239.65K | $-8.58M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $2.68M | (m) | $337.47K | $-9.51M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $3.19M | (m) | $571.92K | $-10.82M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $3.13M | (m) | $717.80K | $-7.98M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $3.97M | (m) | $1.01M | $-9.60M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $4.65M | (m) | $1.08M | $-10.36M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $5.00M | (m) | $996.43K | $-10.52M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $6.09M | (m) | $1.04M | $-12.38M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $6.29M | (m) | $1.69M | $-12.66M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $6.73M | (m) | $1.15M | $-13.24M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $6.55M | (m) | $1.20M | $-13.16M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $6.31M | (m) | $1.32M | $-12.92M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $5.66M | (m) | $1.34M | $-12.15M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $5.55M | (m) | $1.41M | $-11.78M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $5.48M | (m) | $1.44M | $-11.50M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $5.20M | (m) | (m) | $-10.68M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $5.80M | (m) | (m) | $-11.29M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $5.54M | (m) | (m) | $-10.98M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $5.92M | $0.00 | (m) | $-11.50M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $6.80M | (m) | (m) | $-12.38M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $6.50M | (m) | (m) | $-11.76M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $6.32M | (m) | (m) | $-11.20M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $6.57M | $0.00 | (m) | $-10.84M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $5.60M | $0.00 | (m) | $-9.72M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $5.29M | $0.00 | (m) | $-9.43M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $4.83M | $0.00 | (m) | $-8.93M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $4.72M | $6.17K | (m) | $-9.02M | (m) | 76489.55% | (m) | (m) | (m) |
| 2018-09-30 | $5.03M | $13.02K | (m) | $-9.31M | (m) | 38632.52% | (m) | (m) | (m) |
| 2018-06-30 | $4.17M | $300.02K | (m) | $-7.87M | (m) | 1389.59% | (m) | (m) | (m) |
| 2018-03-31 | $3.50M | $357.80K | (m) | $-7.10M | (m) | 979.35% | (m) | (m) | (m) |
| 2017-12-31 | $1.93M | $351.62K | (m) | $-4.63M | $42.63K | 549.19% | (m) | -108.51× | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $495.38K | $515.58K | (m) | $-1.79M | $71.99K | 96.08% | (m) | -24.89× | Reported |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRIDEX CORP (IRIX) | United States | $0.011B | |
| Nuwellis, Inc. (NUWE) | United States | $0.003B | |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Vivani Medical, Inc. (VANI) | United States | $0.111B |